Samsung Bioepis posted the largest Q2 revenue in its history. The company recorded twice as much revenue as in its previous record, and its operating income surpassed what it earned in the entire year last year. This is due to the large influx of milestones, receiving a series of approvals for biosimilars in the U.S. and Europe.

According to Samsung BioLogics on the 25th, Samsung Bioepis posted revenue of KRW 529.9 billion in Q2, up 107.1% from the KRW 259.9 billion a year earlier, and an operating profit of KRW 257.1 billion, up more than six times from the KRW 41.9 billion a year earlier.

Both revenue and operating profit are the largest ever. Samsung Bioepis' Q2 revenue was 89.2% higher t